WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Rama Khaddour, Lena Ramadan and Loai Hasan

ABSTRACT

Background: Fibroids are considered the most common benign pelvic tumor in women, and they arise at the expense of smooth muscle fibers interspersed with connective tissue. They may be symptomatic or asymptomatic, and the severity and quality of symptoms vary according to the location, size, and number of the fibroids, and they need treatment only if they cause symptoms. Objective: Main objective: To compare the clinical and echogenic efficacy of treatment with letrozole and synthetic progestins in the management of fibroids. Second objective: to reduce the use of surgical operations to remove fibroids, and thus reduce the complications resulting from them. Materials and methods: This study is a prospective study that included reviews with clinical symptoms of echogenic fibroids, especially with complaints of menstrual bleeding during the period from March 2022 and March 2023, where the women were divided into two groups: the first was treated with letrozole 2.5 mg daily continuously for 12 weeks. the second treated with progestin (medroxyprogesterone acetate) 150 mg as a single dose for 3 months, and studied the clinical improvement through the decrease in the intensity of menstrual bleeding or dysmenorrhoea and the echo change in the size of the fibroid tumer as a result of treatment, and it was compared between the two groups. The letrozole group included 27 patients and the progestin group 23 patients. Results: The average age of women in the study was (44.15 years), and the average size of the fibroid tumor in the letrozole group was 3.44 cm compared to 3.32 cm in the progestin group. The size of the echogenic fibroid decreased by 42.1% in 85.2% of the letrozole-treated patients and 24.1% in the progestin-treated patients, of while the size remained constant in 7,4% of the letrozole group and 30,4% of the progestins group, and its volume increased in 7,4% of the letrozole group and 17,4% of the progestins group, with a stst Clinically, menstrual bleeding decreased in 85,2% of the letrozole group compared to 82,6% of the progestin group, without a statistically significant difference. Conclusion: Clinical and echogenic improvement was statistically significant in the letrozole and synthetic progestins groups, with letrozole being statistically significantly superior to progestins in echogenic terms. Therefore, it is recommended to conduct more extensive clinical studies on this benefit in preparation for taking it as a conservative treatment in specific cases of fibroids, especially those associated menorrhagia.

[Full Text Article] [Download Certificate]